Difficult to treat asthma at high altitude

Clinical and pathophysiological features of difficult to treat asthma at high altitude.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON26574

Enrollment

150

Registered

2008-04-14

Start date

2007-09-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Difficult to treat asthma Phenotypes of severe asthma Clinical features Pathophysiology High altitude treatment Moeilijk te behandelen astma Fenotypen van ernstig astma Klinische kenmerken Pathofysiologie Hooggebergte behandeling

Interventions

Integrated multidisciplinary assesment of the asthma-control status, asthma history, asthma specific health status, co-morbidity, asthma- triggering factors, medication need, lungfunction, inflammati

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 18-80 year 2. Difficult to treat asthma, defined as uncontrolled asthma despite the chronic use of > 1600 mcg inhaled beclomethason equivalent plus longacting beta-2 agonists or oral steroids. 3. Smoking history 9%.

Exclusion criteria

Exclusion criteria: Exclusion for treatment in Davos: 1. Active cardio-vascular disease 2. Active and acute psychiatric disease in need of treatment by a psychiatrist.

Design outcomes

Primary

Measure	Time frame
Improvement in Asthma-control (ACQ) and FEV1 and decrease in mean oral steroid maintenance dose.	—

Secondary

Measure	Time frame
Improvement in Asthma related Quality of Life (AQLQ), rhinosinusitis score (RSOM-31) fatique score (CIS-Fatique), body mass index (BMI), residual volume as percentage of total lung capacity (RV/TLC), exhaled nitric oxide (FeNO), changes in levels of 25-hydroxyvitamin D and 1.25-(OH)2 vitamin D.	—

Contacts

Public ContactLous H.M. Rijssenbeek-Nouwens

Nederlands Astmacentrum Davos HermanBurckhartstrasse 7260

lrijssenbeek@nad.ch0041 814178000

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)